Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care
AstraZeneca to proceed with regulatory filings to convert from conditional to full approval in the US and EU ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa in... | June 5, 2023
Source: marketscreener.com